Opportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care

dc.contributor.authorBorson, Soo
dc.contributor.authorAu, Rhoda
dc.contributor.authorChodos, Anna H.
dc.contributor.authorGandy, Sam
dc.contributor.authorJain, Holly
dc.contributor.authorAlagor, Amy
dc.contributor.authorCohn, Kristi
dc.contributor.authorKerwin, Diana R.
dc.contributor.authorMintzer, Jacobo
dc.contributor.authorMonroe, Stephanie
dc.contributor.authorRobinson, Delecia
dc.contributor.authorMielke, Michelle M.
dc.contributor.authorWilcock, Donna M.
dc.contributor.departmentNeurology, School of Medicine
dc.date.accessioned2025-04-22T11:14:33Z
dc.date.available2025-04-22T11:14:33Z
dc.date.issued2025-03-11
dc.description.abstractIdentification of early-stage Alzheimer's disease (AD) remains a challenge due to limited specialist availability, diagnostic access, disease awareness, and cultural factors. Blood-based biomarkers (BBBM) could play a critical role in the identification and referral of patients suspected of AD to specialty care. A multidisciplinary AD Biomarker Task Force was convened to evaluate current biomarker use cases, define an optimal biomarker-enabled AD diagnostic care pathway, and understand factors impacting adoption. The Task Force identified opportunities to support biomarker-enabled AD diagnostic care pathway adoption, including streamlining risk assessment and screening by leveraging digital tools, activating primary care providers through education, generating data to expand applicability to diverse populations, and advocating for aligned policies and quality measures. Adoption of BBBMs in the primary care setting will be critical to improve early AD detection. However, challenges to pathway adoption persist and will require action from clinicians, payers, policy makers, and patients to address. Highlights: Blood-based biomarkers can streamline the identification of AD in primary care. Future biomarker-enabled diagnostic care pathways will leverage digital assessments. Education, data generation, and policy advocacy are vital to encourage BBBM use. Implementation of AD care pathways requires the activation of diverse stakeholders.
dc.eprint.versionFinal published version
dc.identifier.citationBorson S, Au R, Chodos AH, et al. Opportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care. Alzheimers Dement (Amst). 2025;17(1):e70095. Published 2025 Mar 11. doi:10.1002/dad2.70095
dc.identifier.urihttps://hdl.handle.net/1805/47280
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/dad2.70095
dc.relation.journalAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourcePMC
dc.subjectAlzheimer's disease
dc.subjectArtificial intelligence (AI)
dc.subjectBlood‐based biomarkers
dc.subjectCare pathway
dc.subjectDigital tools
dc.subjectPrimary care
dc.subjectQuality measure
dc.titleOpportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Borson2025Opportunities-CCBYNC.pdf
Size:
580.57 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: